Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
|
Results for 'Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals December 2011 |
Dec 2011 | £630 | 100% |
| Pharmaceuticals Monthly Deal Analysis - Partnerships, Licensing, Investments and M&A Trends June 2011 |
Jun 2011 | £630 | 99% |
| Biotech M&A and Licensing Strategies Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines |
Apr 2011 | £2,215 | 89% |
| Pharmaceutical Licensing Overview | Mar 2010 | £9,615 | 88% |
| Biotechnology Industry 2010 Yearbook Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions |
Dec 2010 | £2,215 | 87% |
| Stem Cell Research Market to 2017 Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D |
Nov 2011 | £2,215 | 87% |
| Gout Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Mar 2011 | £1,265 | 87% |
| Diabetic Neuropathy Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Mar 2011 | £1,265 | 86% |
| Osteoarthritis Pain Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
May 2011 | £1,265 | 86% |
| Postherpetic Neuralgia (PHN) Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Jun 2011 | £1,265 | 86% |
| Osteosarcoma Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
May 2011 | £1,265 | 85% |
| Cancer Pain Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Apr 2011 | £1,265 | 85% |
| Rheumatoid Arthritis Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Oct 2011 | £2,215 | 85% |
| Dermatophytic Onychomycosis Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
May 2011 | £1,265 | 84% |
| Diabetic Retinopathy Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Mar 2011 | £1,265 | 84% |
| Chronic Pain Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Apr 2011 | £1,265 | 82% |
| Myelodysplastic Syndrome Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Jun 2011 | £1,265 | 81% |
| Postmenopausal Osteoporosis Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Aug 2011 | £1,265 | 81% |
| Insomnia Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Dec 2011 | £2,215 | 81% |
| Top 10 Healthcare Trends in 2011 | Mar 2011 | £2,215 | 81% |
| Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 81% |
| Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 81% |
| Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 81% |
| Prostate Cancer – Germany Drug Forecasts and Treatment Analysis to 2020 |
Nov 2010 | £1,895 | 81% |
| Prostate Cancer – UK Drug Forecasts and Treatment Analysis to 2020 |
Nov 2010 | £1,895 | 81% |
| Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 81% |
| Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 81% |
| Premature Ejaculation (PE) Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Jul 2011 | £1,265 | 81% |
| Ulcerative Colitis Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Sep 2011 | £2,215 | 81% |
| Acute Pain Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Mar 2011 | £1,265 | 81% |
